ResVita Bio develops a skin microbial platform utilizing genetically engineered bacteria to deliver therapeutic proteins directly to affected skin areas, providing continuous treatment for chronic skin diseases. The startup specifically targets conditions such as Netherton Syndrome and atopic dermatitis, addressing the need for sustained, localized therapies that minimize systemic side effects.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Chronic skin diseases often require frequent and invasive treatments, leading to inconsistent therapeutic protein levels and potential systemic side effects. Current therapies struggle to maintain stable drug concentrations in affected areas due to protein instability and short half-lives. This can result in suboptimal treatment outcomes and increased patient burden.
Solution
ResVita Bio is developing a skin microbial platform that uses genetically engineered bacteria to deliver therapeutic proteins directly to the affected skin, providing continuous treatment. This approach transforms skin disease treatment by creating a living system that continuously produces therapeutic agents at the site of the disease. The platform addresses the challenges of protein stability and short half-lives, enabling precise, sustained single or multi-targeted treatments with minimal systemic side effects. By delivering continuous protein therapy, ResVita Bio aims to improve treatment outcomes and reduce the burden on patients with chronic skin conditions.
Target Audience
The primary target audience includes individuals suffering from chronic skin diseases such as Netherton Syndrome, severe atopic dermatitis, chronic wounds, diabetic foot ulcers, and acne vulgaris.
Features
- Genetically engineered bacteria act as living cellular factories to deliver therapeutic proteins.
- Continuous protein therapy enables precise and sustained treatment.
- Topical application designed for patient safety with minimal side effects.
- Targeted delivery of therapeutic proteins directly to affected skin cells.
- Potential to deliver multiple therapies in a single treatment.